Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Travere Therapeutics Inc (TVTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TVTX (5-star) is a STRONG-BUY. BUY since 4 days. Profits (5.50%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $34.43
1 Year Target Price $34.43
| 11 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 53.17% | Avg. Invested days 29 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.62B USD | Price to earnings Ratio - | 1Y Target Price 34.43 |
Price to earnings Ratio - | 1Y Target Price 34.43 | ||
Volume (30-day avg) 15 | Beta 0.75 | 52 Weeks Range 8.46 - 25.29 | Updated Date 08/15/2025 |
52 Weeks Range 8.46 - 25.29 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When Before Market | Estimate -0.2715 | Actual 0.13 |
Profitability
Profit Margin -50.64% | Operating Margin (TTM) -11.05% |
Management Effectiveness
Return on Assets (TTM) -19.28% | Return on Equity (TTM) -705.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1705034008 | Price to Sales(TTM) 4.87 |
Enterprise Value 1705034008 | Price to Sales(TTM) 4.87 | ||
Enterprise Value to Revenue 5.11 | Enterprise Value to EBITDA -5.67 | Shares Outstanding 89138704 | Shares Floating 79289741 |
Shares Outstanding 89138704 | Shares Floating 79289741 | ||
Percent Insiders 0.74 | Percent Institutions 120.08 |
Upturn AI SWOT
Travere Therapeutics Inc
Company Overview
History and Background
Travere Therapeutics Inc. was founded in 2011, initially focused on developing therapies for rare kidney diseases. It has grown through strategic acquisitions and internal development programs, evolving into a commercial-stage biopharmaceutical company.
Core Business Areas
- Rare Kidney Diseases: Focuses on developing and commercializing therapies for rare kidney diseases, including focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).
Leadership and Structure
Eric Dube serves as the CEO. The company has a board of directors and operates with functional departments including research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Filspari (sparsentan): Filspari is approved for the treatment of IgAN. Competitors include Calliditas Therapeutics (TARPEYO), and other emerging therapies in clinical development. Revenue is growing but market share capture is in progress. Analysts expect peak sales exceeding $1 billion.
Market Dynamics
Industry Overview
The biopharmaceutical industry, specifically the rare disease segment, is characterized by high barriers to entry, unmet medical needs, and significant growth potential. It's driven by innovation, regulatory approvals, and market access.
Positioning
Travere Therapeutics focuses on niche therapeutic areas with limited treatment options, offering it a competitive advantage through its specialized knowledge and targeted therapies.
Total Addressable Market (TAM)
The estimated TAM for IgAN and FSGS exceeds $5 billion globally. Travere is positioned to capture a significant portion of this market with Filspari and other pipeline assets.
Upturn SWOT Analysis
Strengths
- FDA-approved therapies
- Strong focus on rare kidney diseases
- Experienced management team
- Established commercial infrastructure
Weaknesses
- Dependence on a limited number of products
- High R&D expenses
- Competition from established pharmaceutical companies
- Market access challenges for rare disease therapies
Opportunities
- Expanding into new rare disease indications
- Strategic partnerships and acquisitions
- Advancements in drug delivery technologies
- Growing awareness of rare kidney diseases
Threats
- Regulatory setbacks
- Clinical trial failures
- Patent expirations
- Pricing pressures from payers
Competitors and Market Share
Key Competitors
- CDTX
- VTRS
- GSK
Competitive Landscape
Travere's advantages include its focused approach on rare kidney diseases and its approved therapies. Disadvantages include its smaller size and limited resources compared to larger pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Travere has experienced growth driven by product launches and expansion of its commercial reach. The historical growth rate varies depending on the period analyzed and is best determined through detailed financial analysis.
Future Projections: Analyst estimates suggest continued revenue growth driven by Filspari uptake and pipeline advancements. These projections are subject to various factors, including regulatory approvals and market conditions.
Recent Initiatives: Recent initiatives include the commercial launch of Filspari, expansion of the pipeline through research and development activities, and strategic partnerships to broaden market access.
Summary
Travere Therapeutics is a growing biopharmaceutical company focused on rare kidney diseases, bolstered by FDA-approved Filspari, yet faces challenges related to competition and market access. While the focus on a niche segment provides a competitive edge, the company should actively diversify the product pipeline and expand commercial reach to secure long-term growth. Potential regulatory hurdles, clinical trial results, and pricing pressures remain significant factors to monitor. The company's innovative approach and focused therapies position it well, but careful risk management is essential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market data is dynamic and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Travere Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2012-11-08 | President, CEO & Director Dr. Eric M. Dube Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 385 | Website https://www.travere.com |
Full time employees 385 | Website https://www.travere.com | ||
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.